白蛋白结合剂偶联FAPI放射性药物用于肿瘤治疗
研究开发了两种白蛋白结合剂偶联的FAPI放射性药物TEFAPI-06和TEFAPI-07,在胰腺癌PDX模型中评估其药代动力学和治疗效果。与177Lu-FAPI-04相比,两种药物显著增强肿瘤摄取和滞留,并显著抑制肿瘤生长,副作用几乎可忽略。
要点
- TEFAPI-06和TEFAPI-07对FAP的亲和力与FAPI-04相当。
- 两种药物在胰腺癌PDX模型中显著增强肿瘤摄取和滞留。
- 177Lu标记的两种药物显著抑制PDX肿瘤生长且副作用几乎可忽略。
核心结论
- 两种白蛋白结合剂偶联的FAPI放射性药物在体内外实验中显著改善肿瘤摄取和滞留,并显著抑制PDX肿瘤生长。
研究设计与样本
- 研究合成了TEFAPI-06和TEFAPI-07,并成功用68Ga、86Y和177Lu标记。
- 进行了细胞实验以鉴定结合亲和力和FAP特异性。
- 在胰腺癌PDX动物模型中进行了PET成像、SPECT成像和生物分布研究。
- 在胰腺癌PDX荷瘤小鼠中评估了177Lu-TEFAPI-06和177Lu-TEFAPI-07的治疗效果。
主要发现
- 68Ga-TEFAPI-06和68Ga-TEFAPI-07对FAP的解离常数分别为10.16 ± 2.56 nM和7.81 ± 2.28 nM,与68Ga-FAPI-04相当。
- 与177Lu-FAPI-04相比,TEFAPI-06和TEFAPI-07的PET成像、SPECT成像和生物分布研究显示其显著增强的肿瘤积累和滞留。
- 177Lu-TEFAPI-06和177Lu-TEFAPI-07观察到显著的肿瘤生长抑制,而对照组和177Lu-FAPI-04治疗组仅显示轻微治疗效果。
临床怎么用
- 这些放射性药物在胰腺癌PDX模型中显示出显著肿瘤生长抑制和几乎可忽略的副作用,有望进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) has become an attractive target for diagnosis and therapy, and a series of FAP inhibitor (FAPI)-based radiotracers has been developed and had excellent performance for diagnosis outcomes in clinical applications. Yet, their fast clearance and insufficient tumor retention have hampered their further clinical application in cancer treatment. In this study, we developed 2 albumin binder-conjugated FAPI radiotracers, TEFAPI-06 and TEFAPI-07. They were derived from FAPI-04 and were optimized by conjugating 2 types of well-studied albumin binders, 4-(p-iodophenyl) butyric acid moiety (TEFAPI-06) and truncated Evans blue moiety (TEFAPI-07), to try to overcome the above limitations at the expense of prolonging the blood circulation. Methods: TEFAPI-06 and TEFAPI-07 were synthesized and labeled with 68Ga, 86Y, and 177Lu successfully. A series of cell assays was performed to identify the binding affinity and FAP specificity in vitro. PET imaging, SPECT imaging, and biodistribution studies were performed to evaluate the pharmacokinetics in pancreatic cancer patient-derived xenograft (PDX) animal models. The cancer treatment efficacy of 177Lu-TEFAPI-06 and 177Lu-TEFAPI-07 were evaluated in pancreatic cancer PDX-bearing mice. Results: The binding affinities (dissociation constants) to FAP of 68Ga-TEFAPI-06 and 68Ga-TEFAPI-07 were 10.16 ± 2.56 nM and 7.81 ± 2.28 nM, respectively, which were comparable with that of 68Ga-FAPI-04. Comparative PET imaging of HT-1080-FAP and HT-1080 tumor-bearing mice and a blocking study showed the FAP-targeting ability in vivo of these 2 tracers. Compared with 177Lu-FAPI-04, PET imaging, SPECT imaging, and biodistribution studies of TEFAPI-06 and TEFAPI-07 demonstrated their remarkably enhanced tumor accumulation and retention, respectively. Notable tumor growth inhibition by 177Lu-TEFAPI-06 and 177Lu-TEFAPI-07 were observed, whereas the control group and the group treated by 177Lu-FAPI-04 showed a slight therapeutic effect. Conclusion: Two albumin binder-conjugated FAPI radiopharmaceuticals have been developed and evaluated in vitro and in vivo. Significantly improved tumor uptake and retention were observed, compared with the original FAPI tracer. Both 177Lu-TEFAPI-06 and 177Lu-TEFAPI-07 showed remarkable growth inhibition of PDX tumors, whereas the side effects were almost negligible, demonstrating that these radiopharmaceuticals are promising for further clinical translational studies.
引用
- Xu M, Zhang P, Ding J, et al. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy. J Nucl Med. 2021. PMID: 34593598. doi:10.2967/jnumed.121.262533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。